Connected Thinking

Leading Voices

Latest News

To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision

PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.

Learn More

Treating Multiple Myeloma in the Second Line: Which Option Should You Choose?

After first-line multiple myeloma treatment, which strategy is best for second-line therapy?

Learn More

Venetoclax vs. BTK Inhibitors in CLL Treatment

In 2019, the FDA approved the combination regimen venetoclax (brand name: Venclexta) plus obinutuzumab (brand Name: Gazyva) as a frontline treatment for chronic lymphocytic leukemia (CLL). Though this combination significantly improves progression-free survival compared with obinutuzumab plus the chemotherapy drug chlorambucil, and it’s a time-limited regimen, the multiple infusions and potential side effects warrant careful consideration.

Learn More

Weighing the Risks of Multiple Myeloma Therapy in the Time of COVID-19

As the COVID-19 pandemic spread across the country, cancer specialists had to weigh the risks of treating multiple myeloma to prevent morbidity and mortality, with the dangers of virus exposure in their patients. SurvivorNet's experts say treatment decisions often hinge on geographic location.

Learn More

What COVID-19 May Have Changed Forever About Multiple Myeloma Care — Telemedicine

COVID made oncologists rethink how to deliver care to their multiple myeloma patients, who are already at higher risk for infection. Providers increasingly shifted to telemedicine, and quickly realized its long-term benefits -- particularly for patients living far from major cancer centers.

Learn More

What Physicians Can Do to Tackle Issues of Race in Cancer Screening and Treatment

Disparities in screenings among those with a family history of cancer are clearly documented in the medical literature. Still, little has changed in our practice to address them.

Learn More

What to Consider Before Prescribing a BTK Inhibitor Such as Calquence for CLL Patients

Bruton kinase (BTK) inhibitors have only emerged in recent years, but already they have become an established therapy for chronic lymphocytic leukemia (CLL) and other hematologic malignancies. Second-generation BTK inhibitors such as acalabrutinib tend to have a better safety profile than the first-generation drugs, but side effects are still a concern.

Learn More

What We’re Learning About Isatuximab and How It’s Being Used to Treat Multiple Myeloma Patients

The recent FDA approval of isatuximab in combination with pomalidomide and dexamethasone has opened up another avenue of treatment for multiple myeloma patients who have already undergone two prior lines of therapy.

Learn More